Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Zymeworks Inc.
Zymeworks Inc. ZYME | 0.00 |
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:
ZYME) with a Overweight and raises the price target from $34 to $37.